Results 1 to 10 of about 286,742 (224)

Heyde syndrome secondary to hypertrophic obstructive cardiomyopathy: a case report [PDF]

The Egyptian Heart Journal
Background Heyde syndrome is an uncommon clinical condition characterized by the triad of aortic stenosis, gastrointestinal angiodysplasia, and acquired von Willebrand syndrome.
Abraham Castellanos-Maldonado, Gustavo Abraham Canales-Azcona, José Luis Martínez-Arroyo, Miguel Maldonado-Valdéz, Héctor Raúl Ibarra-Sifuentes   +4 more
doaj   +3 more sources

Mitral Transcatheter Edge-to-Edge Repair in Non-Surgical Candidates with Hypertrophic Obstructive Cardiomyopathy: Clip It, or Ablate It? [PDF]

Journal of Cardiovascular Development and Disease
Hypertrophic cardiomyopathy (HCM), with or without obstructive phenomena, remains underdiagnosed and undertreated. This condition often involves pathological changes in the mitral valve leaflets and apparatus, which can lead to relevant mitral ...
Emmanouil Chourdakis, Kambis Mashayekhi, Ulrich Schäfer, Christos Katsouras   +3 more
doaj   +2 more sources

HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY

Alʹmanah Kliničeskoj Mediciny, 2016
Hypertrophic cardiomyopathy (HCMP) is a relatively common disease with genetic predisposition, that is widely spread irrespective of gender, race or ethnicity. The cause of this pathology are mutations of genes encoding synthesis of contracting proteins.
A. G. Osiev, R. A. Naydenov, E. I. Kretov, N. R. Obedinskaya, V. P. Kurbatov   +4 more
doaj   +3 more sources

Hypertrophic obstructive cardiomyopathy [PDF]

The Lancet, 2017
Hypertrophic obstructive cardiomyopathy is an inherited myocardial disease defined by cardiac hypertrophy (wall thickness ≥15 mm) that is not explained by abnormal loading conditions, and left ventricular obstruction greater than or equal to 30 mm Hg. Typical symptoms include dyspnoea, chest pain, palpitations, and syncope.
Veselka, Josef, Anavekar, Nandan, Charron, Philippe   +2 more
openaire   +4 more sources

Hypertrophic Obstructive Cardiomyopathy [PDF]

Deutsches Ärzteblatt international, 2019
Hypertrophic cardiomyopathy (HCM) is caused by mutations in a number of genes. Its prevalence is 0.2% to 0.6%.This review is based on publications retrieved by a selective literature search and on the authors' clinical experi- ence.70% of patients with HCM suffer from the obstructive type of the condition, clinically characterized by highly dynamic and
Angelika, Batzner, Hans-Joachim, Schäfers, Konstantin V, Borisov, Hubert, Seggewiß   +3 more
openaire   +3 more sources

Clinical Efficacy and Safety of Cox-Maze IV Procedure for Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy

Frontiers in Cardiovascular Medicine, 2021
Objective: Atrial fibrillation is the most prevalent persistent arrhythmia in patients with hypertrophic obstructive cardiomyopathy. Comparative analyses of the safety and effectiveness of septal myectomy with and without surgical ablation are limited ...
Yanhai Meng, Yanbo Zhang, Ping Liu, Changsheng Zhu, Tao Lu, Enci Hu, Qiulan Yang, Changrong Nie, Shuiyun Wang   +8 more
doaj   +1 more source

Periprocedural, Short-Term, and Long-Term Outcomes of Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A 20-Year Single-Center Experience

Anatolian Journal of Cardiology, 2022
Background: Alcohol septal ablation is recommended for hypertrophic obstructive cardiomyopathy patients who had refractory symptoms despite optimal medical treatment.
Umut Karabulut, Yeşim Yılmaz Can, Egemen Duygu, Dilay Karabulut, Kudret Keskin, Tuğrul Okay   +5 more
doaj   +1 more source

Echocardiography for hypertrophic obstructive cardiomyopathy

Annals of Cardiac Anaesthesia, 2017
Kalpna Irpachi, K Ashok Kumar, Poonam Malhotra Kapoor   +2 more
doaj   +3 more sources

Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Information on impact of race and ethnicity on use and early outcomes of septal reduction therapies (SRTs) for obstructive hypertrophic obstructive cardiomyopathy are limited.
Sri Harsha Patlolla, Hartzell V. Schaff, Rick A. Nishimura, Mackram F. Eleid, Jeffrey B. Geske, Steve R. Ommen   +5 more
doaj   +1 more source

Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

Circulation: Cardiovascular Interventions, 2013
Hypertrophic cardiomyopathy (HCM) is a common, yet challenging condition for clinical management. The majority of these patients have evidence of left ventricular outflow tract (LVOT) obstruction that may be asymptomatic or associated with debilitating symptoms of heart failure.
Paul, Sorajja, Steve R, Ommen, Rick A, Nishimura   +2 more
openaire   +2 more sources